{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:22:16Z","timestamp":1786980136362,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00415-021-10544-3","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T15:04:42Z","timestamp":1617807882000},"page":"3871-3877","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis"],"prefix":"10.1007","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2584-5793","authenticated-orcid":false,"given":"Adi","family":"Wilf-Yarkoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itay","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"10544_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","volume":"48\u201349","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B (2014) Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun 48\u201349:143\u2013148","journal-title":"J Autoimmun"},{"key":"10544_CR2","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia Gravis. N Engl J Med 375:2570\u20132581","journal-title":"N Engl J Med"},{"key":"10544_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036","journal-title":"Lancet Neurol"},{"key":"10544_CR4","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","volume":"48","author":"A Vincent","year":"1985","unstructured":"Vincent A, Newsom-Davis J (1985) Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48:1246\u20131252","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10544_CR5","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1093\/brain\/awg223","volume":"126","author":"A Evoli","year":"2003","unstructured":"Evoli A, Tonali PA, Padua L et al (2003) Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain J Neurol 126:2304\u20132311","journal-title":"Brain J Neurol"},{"key":"10544_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","volume":"52","author":"P Zisimopoulou","year":"2014","unstructured":"Zisimopoulou P, Evangelakou P, Tzartos J et al (2014) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 52:139\u2013145","journal-title":"J Autoimmun"},{"key":"10544_CR7","doi-asserted-by":"publisher","first-page":"577080","DOI":"10.1016\/j.jneuroim.2019.577080","volume":"337","author":"EB Souto","year":"2019","unstructured":"Souto EB, Lima B, Campos JR, Martins-Gomes C, Souto SB, Silva AM (2019) Myasthenia gravis: State of the art and new therapeutic strategies. J Neuroimmunol 337:577080","journal-title":"J Neuroimmunol"},{"key":"10544_CR8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3389\/fneur.2020.00604","volume":"11","author":"ME Farrugia","year":"2020","unstructured":"Farrugia ME, Goodfellow JA (2020) A practical approach to managing patients with myasthenia gravis-opinions and a review of the literature. Front Neurol 11:604","journal-title":"Front Neurol"},{"issue":"1","key":"10544_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/mus.26114","volume":"58","author":"NM Engel-Nitz","year":"2018","unstructured":"Engel-Nitz NM, Boscoe A, Wolbeck R, Johnson J, Silvestri NJ (2018) Burden of illness in patients with treatment refractory myasthenia gravis. Muscle Nerve 58(1):99\u2013105","journal-title":"Muscle Nerve"},{"key":"10544_CR10","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","volume":"15","author":"NJ Silvestri","year":"2014","unstructured":"Silvestri NJ, Wolfe GI (2014) Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis 15:167\u2013178","journal-title":"J Clin Neuromuscul Dis"},{"key":"10544_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/mus.26156","volume":"58","author":"G Beecher","year":"2018","unstructured":"Beecher G, Anderson D, Siddiqi ZA (2018) Rituximab in refractory myasthenia gravis: Extended prospective study results. Muscle Nerve 58:452\u2013455","journal-title":"Muscle Nerve"},{"key":"10544_CR12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"S Muppidi","year":"2019","unstructured":"Muppidi S, Utsugisawa K, Benatar M et al (2019) Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60:14\u201324","journal-title":"Muscle Nerve"},{"key":"10544_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1196\/annals.1405.001","volume":"1132","author":"P Gajdos","year":"2008","unstructured":"Gajdos P, Chevret S (2008) Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin. Ann N Y Acad Sci 1132:271\u2013275","journal-title":"Ann N Y Acad Sci"},{"key":"10544_CR14","first-page":"Cd002277","volume":"12","author":"P Gajdos","year":"2012","unstructured":"Gajdos P, Chevret S, Toyka KV (2012) Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 12:Cd002277","journal-title":"Cochrane Database Syst Rev"},{"key":"10544_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000502818","volume":"81","author":"G Karelis","year":"2019","unstructured":"Karelis G, Balasa R, De Bleecker JL et al (2019) A phase 3 multicenter, prospective, open-label efficacy and safety study of immune globulin (human) 10% caprylate\/chromatography purified in patients with myasthenia gravis exacerbations. Eur Neurol 81:223\u2013230","journal-title":"Eur Neurol"},{"key":"10544_CR16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","volume":"68","author":"L Zinman","year":"2007","unstructured":"Zinman L, Ng E, Bril V (2007) IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68:837\u2013841","journal-title":"Neurology"},{"key":"10544_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","volume":"15","author":"MC Dalakas","year":"2019","unstructured":"Dalakas MC (2019) Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol 15:113\u2013124","journal-title":"Nat Rev Neurol"},{"key":"10544_CR18","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1055\/s-0037-1613331","volume":"88","author":"RJ Hansen","year":"2002","unstructured":"Hansen RJ, Balthasar JP (2002) Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost 88:898\u2013899","journal-title":"Thromb Haemost"},{"key":"10544_CR19","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/MOH.0000000000000609","volume":"27","author":"PAA Norris","year":"2020","unstructured":"Norris PAA, Kaur G, Lazarus AH (2020) New insights into IVIg mechanisms and alternatives in autoimmune and inflammatory diseases. Curr Opin Hematol 27:392\u2013398","journal-title":"Curr Opin Hematol"},{"key":"10544_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<551::AID-MUS14>3.0.CO;2-O","volume":"23","author":"A Achiron","year":"2000","unstructured":"Achiron A, Barak Y, Miron S, Sarova-Pinhas I (2000) Immunoglobulin treatment in refractory Myasthenia gravis. Muscle Nerve 23:551\u2013555","journal-title":"Muscle Nerve"},{"issue":"2","key":"10544_CR21","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/ene.14547","volume":"28","author":"M Alcantara","year":"2020","unstructured":"Alcantara M, Sarpong E, Barnett C, Katzberg H, Bril V (2020) Chronic immunoglobulin maintenance therapy in myasthenia gravis. Eur J Neurol 28(2):639\u2013646","journal-title":"Eur J Neurol"},{"key":"10544_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jns.2013.10.043","volume":"338","author":"MA Hellmann","year":"2014","unstructured":"Hellmann MA, Mosberg-Galili R, Lotan I, Steiner I (2014) Maintenance IVIg therapy in myasthenia gravis does not affect disease activity. J Neurol Sci 338:39\u201342","journal-title":"J Neurol Sci"},{"key":"10544_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/00002826-200105000-00010","volume":"24","author":"O Hilkevich","year":"2001","unstructured":"Hilkevich O, Drory VE, Chapman J, Korczyn AD (2001) The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis. Clin Neuropharmacol 24:173\u2013176","journal-title":"Clin Neuropharmacol"},{"key":"10544_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki","year":"2000","unstructured":"Jaretzki A, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the myasthenia gravis foundation of america. Neurology 55:16\u201323","journal-title":"Neurology"},{"key":"10544_CR25","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.nmd.2019.06.002","volume":"29","author":"RH Roda","year":"2019","unstructured":"Roda RH, Doherty L, Corse AM (2019) Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis. Neuromuscul Disord 29:554\u2013561","journal-title":"Neuromuscul Disord"},{"key":"10544_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J (2019) Myasthenia gravis. Nat Rev Dis Primers 5:30","journal-title":"Nat Rev Dis Primers"},{"key":"10544_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","volume":"7","author":"RA Hughes","year":"2008","unstructured":"Hughes RA, Donofrio P, Bril V et al (2008) Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7:136\u2013144","journal-title":"Lancet Neurol"},{"key":"10544_CR28","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2165\/00003495-200969080-00004","volume":"69","author":"K Kuitwaard","year":"2009","unstructured":"Kuitwaard K, van Doorn PA (2009) Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy. Drugs 69:987\u20131001","journal-title":"Drugs"},{"key":"10544_CR29","first-page":"962530","volume":"2014","author":"O Dolezal","year":"2014","unstructured":"Dolezal O (2014) Intravenous immunoglobulin treatment in chronic neurological diseases: do we have maintenance dose right? Autoimmune Dis 2014:962530","journal-title":"Autoimmune Dis"},{"key":"10544_CR30","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","volume":"89","author":"MK Hehir","year":"2017","unstructured":"Hehir MK, Hobson-Webb LD, Benatar M et al (2017) Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology 89:1069\u20131077","journal-title":"Neurology"},{"key":"10544_CR31","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16:976\u2013986","journal-title":"Lancet Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10544-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10544-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10544-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T16:10:24Z","timestamp":1698855024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10544-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10544"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10544-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"13 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data gathered after approval by the Ethics Committee of Rabin Medical Center and therefore been performed in accordance with the ethical standards laid down in the 1964 declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The Institutional Review Board for human experiments waived informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}